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Abstract: 
 
Several analogs of gigantol (1) were synthesized to evaluate their effect on the complexes Ca2+–
calmodulin (CaM) and Ca2+–CaM–CaM sensitive phosphodiesterase 1 (PDE1). The compounds 
belong to four structural groups including, 1,2-diphenylethanes (2–11), diphenylmethanes (13–
15), 1,3-diphenylpropenones (16–18), and 1,3-diphenylpropanes (20–22). In vitro enzymatic 
studies showed that all compounds except 11 inhibited the complex Ca2+–CaM–PDE1 with 
IC50 values ranging from 9 to 146 μM. On the other hand, all analogs but 11, 12 and 15 quenched 
the extrinsic fluorescence of the CaM biosensor hCaM–M124C–mBBr to different extent, then 
revealing different affinities to CaM; their affinity constants (Km) values were in the range of 3–
80 μM. Molecular modeling studies indicated that all these compounds bound to CaM at the 
same site that the classical inhibitors trifluoperazine (TFP) and chlorpromazine (CPZ). Some of 
these analogs could be worthy candidates for developing new anti-tumor, local anesthetics, 
antidepressants, antipsychotic, or smooth muscle relaxant drugs, with anti-CaM properties due to 
their good affinity to CaM and the straightforwardness of their synthesis. In addition they could 
be valuable tools for the study of Ca2+–CaM functions. 
 
Graphical abstract: Some synthetic 1,2-diphenylethanes, diphenylmethanes, 1,3-
diphenylpropenones, and 1,3-diphenylpropanes inhibited Ca2+–CaM–PDE1 complex and 
quenched the fluorescence of hCaM–M124C–mBBr. 
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Article: 
 
1. Introduction 
 
Gigantol (1) is a naturally occurring 1,2-diphenylethane (bibenzyl) isolated from several 
medicinal orchids. In previous investigations, the anti-inflammatory, antinociceptive, phytotoxic, 
and spasmolytic properties of 1 and a few synthetic 1,2-diphenylethanes were 
demonstrated [1], [2], [3], [4], [5]. It was also found that for maximum spasmolytic activity, 
these products should have oxygenated substituents on both aromatic rings [5]. The spasmolytic 
1,2-diphenylethanes or bibenzyls also inhibited the complex Ca2+–calmodulin (CaM)–CaM-
sensitive phosphodiesterase 1 (PDE1) and potentiated the antispasmodic action 
of chlorpromazine (CPZ), a classical CaM inhibitor [5]. Altogether, these results suggested that 
these compounds were CaM inhibitors and that their smooth muscle relaxant activity was 
mediated by CaM [1], [5]. 
 
CaM is a major cellular Ca2+–binding protein, which is ubiquitously expressed in all the 
eukaryotic cells [6]. This protein does not possess enzymatic activity, however modulates several 
enzymes and ion channels involved in a variety of physiological events including regulation 
of metabolism, cytoskeleton, ion transport, protein folding, cell proliferation, cell division as 
well as protein phosphorylation and dephosphorylation, among others. Therefore, Ca2+–CaM and 
Ca2+–CaM-protein complexes are of significant biomedical interest as molecular targets for the 
development of new drugs useful for treating pathological processes related with CaM [7]. 
Indeed, CaM-induced target enzyme activation can be blocked by several classes of 
pharmacological effectors: antipsychotics, antidepressants, muscle relaxants, and 
local anesthetics. 
 
In this study we describe the synthesis and the anti-CaM effect (in vitro and in silico) of twenty 
compounds (2–22) structurally related to gigantol (1), which on the basis of the above 
considerations could be a suitable lead for the discovery of new CaM antagonists. As 
compound 1, analogs 2–11 contain an ethylene bridge and two aromatic rings, with oxygenated 
or nitrogenated substituents of diverse polarity in different positions; these modifications would 
be useful for ascertaining the influence of the nature and location of the substituents along the 
1,2-diphenylethane core on the anti-CaM effect of gigantol (1). Compound 12, includes a 
heteroatom in the bridge and possesses no subtituents at the aromatic rings. On the other hand, to 
assess the contribution of the size and nature of the carbon chain between the two phenyls, 
analogs 13–22 were also analyzed. Analogs 13–15 are diphenylmethanes, 16–18 1,3-
diphenylpropenones (chalcones), and 20–22 are 1,3-diphenylpropanes. Thus, the last three set of 
compounds differ in the number of carbon atoms linking the two aromatic rings and their degree 
of oxidation. It is important to point out that diphenylmethanes, 1,3-diphenylpropanes or the 
chalcones have not previously tested as anti-CaM agents therefore the corresponding scaffold 
could be a new leads for the development of new CaM antagonists. 
 
2. Results and discussion 
 
Compounds 1–10 were obtained using the Wittig reaction, a method widely used for the 
synthesis of 1,2-diphenylethanes [5]. In all cases, the phosphonium salts were prepared by the 
reaction of triphenylphosphine with an appropriated alkyl halide; the resulting salts were 
dissolved in THF and deprotonated with NaH to yield a mixture of Z- and E-stilbenes, which 
were reduced by treatment with catalytic amounts of 10% Pd–C over H2 (4 atm) to afford the 
1,2-diphenylethanes [5]; the general route employed is summarized in Scheme 1. The yields 
ranged from 41 to 72%. Compounds 4–7, 9, and 10 are new chemical entities, while 3 was 
isolated from a Dendrobium species [8]. Finally, bibenzyls 2 and 8 were previously 
synthesized [9]. Diphenylmethanes 13 and 14 were obtained by an acid catalyzed intramolecular 
rearrangement of benzyl phenyl ether 26 (Scheme 2), which in turn was prepared by an O-
alkylation of guaiacol with 3,5-dimethoxybenzyl bromide (25) in basic conditions [10]. 
Chalcones 16–19 were synthesized via a base catalyzed aldol condensation of the appropriate 
acetophenone (27a–27c) with a suitable benzaldehyde derivative (24b, 24c and 24g–24h). 
Finally, 1,3-diphenylpropanes 20–22 were obtained by one-step catalytic reduction of 
chalcones 16 [11], 18, and 19 using H2SO4 and 10% Pd/C, in ethanol at 60 °C (Scheme 3). 
Compounds 17–22 are reported by the first time. The structures of synthetic analogs 1–
11, 13, 14, and 17–22 were elucidated on the basis of 1D-, 2D-NMR, and MS studies. 
 
 
Scheme 1. Reagents and conditions for the synthesis of 1,2-diphenylethanes 1–10: (a) NaH, 
THF; (b) H2, 10% Pd–C, EtOAc. 
 
 
Scheme 2. Reagents and conditions for the synthesis of compounds 13 and 14: (a) guaiacol, 
K2CO3, acetone; (b) H3PO4, toluene. 
 
 
Scheme 3. Reagents and conditions for the synthesis of 1,3-diphenylpropenones 16–19 and 1,3-
diphenylpropanes 20–22: (a) KOH, EtOH; (b) Pd–C 10%, EtOH–H2SO4. 
 
The in vitro anti-CaM activity of compounds 1–18 and 20–22 was determined using two 
methodologies; the first one, enzymatic in nature, employed PDE1 as monitoring enzyme and, 
assesses the action of the test compounds on the complex Ca2+–CaM–PDE1 [12], [13]. The 
second analysis measures the direct interaction and affinity of any compound to the complex 
Ca2+–CaM; for this assay a hCaM M124C–mBBr fluorescent biosensor was used [14]. The 
results (Table 1 and Fig. 1) showed that all compounds but 11, 12, and 15 did not bind to the 
complex Ca+2–CaM. These three compounds have in common the absence of substituents in 
rings A and B of the 1,2-diphenylethane, diphenylmethane or benzylphenoxy cores (see Scheme 
1) suggesting that the substitution at both aromatic rings, regardless of the nature and number of 
the bridge carbons, is an important structural feature for Ca+2–CaM binding. This assumption 
was further confirmed throughout the docking analysis (vide infra, Table 1). In any case, 
however, the position of the phenols did not have a clear impact on the affinity to the protein. 
 
Regarding their effect on the complex Ca2+–CaM–PDE1, 11 and 12 did not inhibit 
the hydrolysis of cAMP; however 15 clearly displayed an inhibitory effect of the enzymatic 
activity with an IC50 of 15 μM. The latter results suggested that 15 could be affecting any 
components enzymatic assay including the snake nucleotidase or the PDE1. These results 
showed the pitfalls of the enzymatic assay and the robustness of direct measurements using 
a hCaM M124C–mBBr fluorescent biosensor. 
 
Table 1. Activity on the Ca+2–CaM–PDE1 and properties of binding on the Ca+2–CaM complex 
of compounds 1–22. 
Compound Enzymatic PDE1 assay Fluorescence quenching 
IC50 (μM)a Km (μM)b hc 
CPZ 10.3 ± 1.02 5.55 ± 0.09 1.28 ± 0.02 
1 114.18 ± 6.17 60.82 ± 4.12 1.23 ± 0.04 
2 9.38 ± 2.48 80.04 ± 6.17 0.96 ± 0.05 
3 31.29 ± 5.12 45.48 ± 1.98 1.59 ± 0.06 
4 18.44 ± 6.53 9.88 ± 0.40 2.01 ± 0.12 
5 30.10 ± 2.90 12.03 ± 0.38 1.55 ± 0.05 
6 36.33 ± 7.39 10.00 ± 0.19 2.55 ± 0.12 
7 75.89 ± 9.02 63.77 ± 2.86 1.52 ± 0.06 
8 146.35 ± 32.46 21.82 ± 1.32 2.12 ± 0.14 
9 46.09 ± 4.01 58.08 ± 5.11 1.26 ± 0.13 
10 54.69 ± 6.22 25.26 ± 1.58 1.88 ± 0.20 
11 NI NB NB 
12 NI NB NB 
13 56.15 ± 14.89 33.79 ± 5.06 1.01 ± 0.06 
14 54.73 ± 6.47 33.07 ± 4.58 1.00 ± 0.06 
15 15.02 ± 4.19 NB NB 
16 22.53 ± 6.52 10.27 ± 0.70 1.82 ± 0.17 
17 37.68 ± 6.81 3.89 ± 0.05 1.72 ± 0.03 
18 57.27 ± 15.21 5.31 ± 0.21 1.49 ± 0.05 
20 62.68 ± 3.59 8.70 ± 0.15 1.35 ± 0.03 
21 22.94 ± 4.05 14.21 ± 0.85 0.90 ± 0.03 
22 32.54 ± 6.06 54.33 ± 6.41 0.97 ± 0.06 
NB = not bind. 
NI = not inhibit. 
a Concentration inhibiting by 50% the activity of the enzyme. 
b Apparent constant. 
c Hill coefficient. 
 
The remaining analogs tested showed different affinities to the protein with Km values in the 
range of 3–80 μM. On the other hand, compounds 11, 12 and 8 did not affect the complex Ca+2–
CaM–PDE1; the other compounds (1–7, 9, 10, 13–18, 20–22) however, inhibited the activation 
of PDE1 with IC50 values ranging from 9 to 75 μM. 
 
Among the group of 1,2-diphenylethanes, compounds 4–6 exhibited the highest affinity to the 
protein with Km of 9, 12 and 10 μM, respectively. The better affinity of compound 5 in 
comparison to 1 revealed that the presence of a tertiary amine in ring B increased the affinity to 
the protein by five times. On the other hand, comparison of the Km values of 1 and 10 (Km of 60 
and 25 μM, respectively), clearly indicated that the etherification of the free phenol group at C-4 
in ring B improved the affinity for the protein almost three fold. The lower Km value for 
compound 4 (Km = 9.88 μM), in comparison with 10 (Km = 25.26 μM) further supports this 
comportment. Comparison of the Km values of compounds 4, 10, and 9 (9, 25, and 58 μM, 
respectively) with those of 2, 3, 7,and 8 (Km of 80, 45, 63, and 21 μM, respectively), 
strengthened the relevance of hydrophobic substituents for better affinity to Ca+2–CaM in vitro. 
 
 
Fig. 1. Fluorescence spectra and titration curves of Ca2+–hCaM–M124C–mBBr in the presence 
of CPZ (A), 4 (B), 11 (C), and 18 (D). Buffer was 100 mM of potassium acetate (pH 5.1) at 
37 °C and 1 mM CaCl2. Samples were excited at 381 nm, and emission spectra recorded for light 
scattering effects from 400 to 550 nm. The absolute changes of maximal fluorescence 
emission ware plotted against the ration compounds/protein total and fitted to the binding 
equation model to obtain the Km. 
 
In the enzymatic study, in general the 1,2-diphenylethanes showed a similar trend of effects 
(Table 1) since compounds 4–6 were among those that clearly inhibited the activation of PDE1 
with IC50 between 18 and 36 μM. The exception was compound 15 which did not bind to Ca2+–
CaM but showed good inhibitory effect of the enzymatic activity of the complex Ca2+–CaM–
PDE1. This effect could be due to a direct interaction of 15 with PDE1. 
 
In the group of diphenylmethanes, 13 and 14 showed similar affinity to CaM (Km values 
∼33 μM) as well as similar inhibitory effect on enzymatic activity of the complex Ca+2–CaM–
PDE1. Compared with all compounds tested, their affinity to CaM was comparable to that of 
compound 10. 
 
The 1,3-diphenylpropanes 20–22 showed Km values ranged between 8.7 and 54 μM, being 20 the 
most affine. Comparison of the Km values of compounds 21 and 7 indicated that the increment of 
the chain length between the two phenyl rings increases the affinity to Ca+2–CaM. This 
difference could be due to the highest conformational flexibility of 1,3-diphenylpropanes in 
comparison to 1,2-diphenylethanes which allows better coupling of the former group to the 
protein, as could be inferred from the docking analysis (vide infra). 
 
During the preparation of compounds 20 and 22, chalcones 16–19 were obtained as 
intermediates and thereafter included in this study. The results summarized in Table 1 indicated 
that intermediates 17 and 18 displayed the highest affinity to Ca+2–CaM among all compounds 
tested. Indeed, comparison of 1, 18 and 22(Km = 60.8, 5.3 and 54.3 μM) revealed that the 
presence of a conjugated ketone group between the two phenyl rings significantly increased the 
affinity for CaM. However, comparison between 16 and 20 (Km = 10.2 and 8.7 μM) indicated 
that the substitution pattern in the two rings could be more important that the nature of the chain 
linking them. The better affinity of compound 17 over the remaining compounds could be also 
explained in terms of structural energy; thus, according with the docking analysis, 17 shows 
one hydrogen bond interaction (vide infra). 
 
Altogether, the results revealed that among similar compounds those possessing hydrophobic 
substituents had the best affinity for the complex Ca+2–CaM and better inhibitory effect of the 
complex Ca+2–CaM–PDE1, being the most relevant compounds 1,2-diphenylethane 4, 
chalcones17 and 18 as well as 1,3-diphenylpropane 20. In most cases the better affinity for the 
protein correlated with the inhibitory effect of the enzyme activity. 
 
2.1. Docking 
 
To investigate the binding mode of gigantol (1) analogs to CaM (PDB code 1LIN), docking 
studies were performed using the program AUTODOCK 4.0.2 [15], [16]. Those compounds 
exhibiting the highest affinity to the protein, according to the fluorescence assay, were selected; 
accordingly, the structures of compounds 4, 11, 13, 17 and 20 were optimized with the 
program Gaussian 09 using the density functional theory method (DFT) at the B3LYP/3-21g 
level. Initially, the ligands were docked to the entire protein; then, the best conformations were 
docked in a smaller area (grid) in order to refine the results. The compounds analyzed bound to 
the pocket corresponding to sites I, IV, IV and IV, respectively (Fig. 2) as TFP, a classical 
CaM antagonist [17]. Fig. 2 shows the theoretical binding model of 4, 13, 17 and 20, 
superimposed with the X-ray structure of the protein with the classical inhibitor TFP. In all 
cases, regardless of the binding site, one of the two phenyl groups of the scaffold sink in the 
hydrophobic pockets establishing contact similar to those of TFP or W7, which are classical 
inhibitors of CaM [18]. In the case of compound 4, the binding site in the docking model consists 
of Phe92, Leu105, Met109, Met124, Glu127, Ala128, Val136, and Met144. 
Compound 13 binding site comprises Phe19, Leu32, Met51, Glu54, Val55, Ile-53, and Phe68. 
Compound 17 binding pocket includes Phe19, Leu32, Val35, Met36, Leu39, Gln41, Ile63, 
Phe68, Met51, Ile52, and Val55. Finally, in the case of 20, Phe19, Met51, Ile52, Val55, Ile63, 
Phe68 and Met71 were part of the pocket. Although there are not clear clues of which are the 
structural features responsible for the affinity of these compounds to CaM, the highest affinity 
of 17 to the protein might be due to differences in the contact surfaces and/or protein 
conformation upon interaction of the ligands, despite some common amino acid residues at the 
binding sites; additionally this compound show one hydrogen bond interactions between 
Met51/O and hydroxyl in the position R2 of 17. The results of the docking study revealed also 
those compounds 4, 13, 17 and 20 form mainly hydrophobic and/or π–π interactions with the 
protein as does AAA. In the case of compound 11, the docking study predicted no binding to the 
classical CaM binding sites I–IV (Fig. 2). 
 
 
Fig. 2. Binding model of compounds with the complex Ca2+–CaM. CaM is represented in green 
cartoon. The TFP is depicted in black lines, compound 4 in red sticks, 11 in cyan sticks, 13 in 
blue sticks, 17 in magenta sticks and 20 in yellow stick. Hydrophobic pockets are show in 
surface and interacting amino acids within the CaM-ligands complex of the compounds 4(A), 
13(B), 17(C) and 20(D). This figure was geared up using the program PyMOL.  
 
3. Conclusions 
 
Several 1,2-diphenylethanes, 1,3-diphenylpropenones, diphenylmethanes, and 1,3-
diphenylpropanes with CaM inhibitor properties were discovered. The simplicity and good yields 
of their synthesis make these compounds good candidates for the development of new CaM-
inhibitors. Although there are not clear clues of what are the structural features responsible for 
the affinity of these compounds to CaM, some of them showed better affinity for the protein than 
gigantol (1) and CPZ [18]. The best ligand was chalcone 17 with a Km value of 3.89 μM. Among 
the 1,2-diphenylethanes and 1,3-diphenylpropanes, only derivatives 4–6 and 20, respectively, 
possessed good affinity to the protein with Km values approximately six fold than 1. Compounds 
4, 13, 17 and 21 bind to CaM in the same region that the classical inhibitors TFP and W-7 
mainly through hydrophobic, according to a docking analysis. 
 
Once more the results of our study clearly show that different ligands bind differentially to CaM 
complexes (Ca2+–CaM or Ca2+–CaM–PDE1) which could have different implications at 
physiological level. Thus, in the present work compound 15 did not bind to Ca2+–CaM but 
showed good inhibitory effect of the enzymatic activity of the complex Ca2+–CaM–PDE1; 
however, further work is needed to demonstrate the 15 selectively bind to the complex Ca2+–
CaM–PDE1or to PDE1. The relevance of differentially activate one particular complex could 
result in selective pharmacological activity and a decrease of side effects of any potential drug. 
 
4. Experimental 
 
4.1. Chemistry 
 
4.1.1. General experimental procedures 
 
Melting points were determined on a Fisher-Johns apparatus and are uncorrected. IR spectra 
were obtained using KBr disks on a Perkin–Elmer FT 1605 spectrophotometer. NMR spectra 
were recorded in CDCl3 on a Varian Unity Plus 500 spectrometer either at 300 and 400 (1H) or 
100 (13C) MHz, using tetramethylsilane (TMS) as an internal standard. Electron-impact mass 
spectra (EIMS) were registered on a JEOL SX 102 mass spectrometer. Open column 
chromatography was carried out on silica gel 60 (70–230 mesh, Merck, Darmstadt, Germany). 
Analytical and preparative TLC was performed on precoated silica gel 60 F254 plates (Merck, 
Darmstadt, Germany). 
 
4.1.2. Synthetic intermediates 
 
Diphenylethane (11), benzyl phenyl ether (12), diphenylmethane (15), 4-benzyloxy-3-
methoxybenzaldehyde (24a), 4-methoxybenzaldehyde (24b), 3,4-(methylenedioxy)benzaldehyde 
(23c), 4-ethoxy-3-methoxybenzaldehyde (24d), 4-(dimethylamino)benzaldehyde (24e), 3-
hydroxy-4-methoxybenzaldehyde (24f), 4-hydroxy-3-methoxybenzaldehyde (24g), 4′-
hydroxyacetophenone (27a), 3′-hydroxy-5′-methoxyacetophenone (27b), 3′-
hydroxyacetophenone (27c), and guaiacol were purchased from Sigma–Aldrich (St Louis, MO, 
USA). 3-Benzyloxy-5-methoxybenzyltriphenylphosphonium bromide (23a), 3-
hydroxybenzyltriphenylphosphonium bromide (23b), 3,5-
dimethoxybenzyltriphenylphosphonium bromide (23c), and 3,5-dimethoxybenzyl bromide (25), 
were prepared as previously described in Ref. [5]. 
 
4.1.3. General procedure for the synthesis of 1,2-diphenylethanes 1–10 
 
The Wittig salt (23a–23c; 4.4 mmol) and NaH (4.5 mmol) were dissolved in dry tetrahydrofuran 
(50 mL) under a N2 atmosphere; then, the appropriated aromatic aldehyde (24a–24e; 4.4 mmol) 
was added to the mixture, which was stirred during 3 h at room temperature. After this period of 
time, water was added and the product extracted with EtOAc. The resulting organic phases were 
washed with brine and water, dried (anh. Na2SO4) and evaporated in vacuo to give crude oily 
residues which were purified by open column chromatography (silica gel; 30 g), hexane-EtOAc 
to yield a mixture of Z- and E-stilbenes; the mixture were directly hydrogenated at 60 lb/in2 
(30 °C) in EtOAc (40 mL) over 10% palladium on carbon (0.1 g) for 3 h; the catalyst was then 
filtered off, and the resulting mixtures evaporated to dryness. These crude reaction mixtures were 
then purified by open column chromatography to give the final products 1–10. In all cases, for 
1 g of crude reaction mixture the chromatographic column was packed with 30 g of silica gel. 
The eluents consisted in mixtures of hexane-CH2Cl2 (1:1 → 0:1) and CH2Cl2–MeOH 
(1:0 → 9:1). 
 
4.1.3.1. 4-[2-(3-Hydroxy-5-methoxyphenyl)ethyl]-2-methoxyphenol (1) 
 
The pure compound 1 (0.47 g, yield 41.3%) was obtained as a colorless oil and was identical to a 
reference standard isolated from Scaphyglottis livida (Orchidaceae) [19]. 
 
4.1.3.2. 3-Methoxy-5-[2-(4-methoxyphenyl)ethyl]phenol (2) 
 
Compound 2 was obtained as an amber oil (0.47 g, yield 41%); UV (MeOH) λmax 276, 208 nm; 
IR (KBr) vmax 3401, 2933, 1597, 1453, 1244, 1148 cm−1; 1H NMR (400 MHz, CDCl3) δ 2.75–
2.85 (4H, m, H-7, H-7′), 3.75 (3H, s, CH3O-5), 3.79 (3H, s, CH3O-4′), 4.77 (1H, s, HO-3), 6.25 
(2H, d, J = 1.8 Hz, H-2, H-6), 6.32 (1H, t, J = 1.8 Hz, H-4), 6.82 (2H, d, J = 8.8 Hz, H-3′, H-5′), 
7.11 (2H, d, J = 8.8 Hz, H-2′, H-6′); 13C NMR (100 MHz, CDCl3) δ 36.8 (C-7′), 38.4 (C-7), 55.5 
(CH3O-4′, CH3O-5), 99.2 (C-4), 107.0 (C-6), 108.0 (C-2), 113.9 (C-3′, C-5′), 129.5 (C-2′, C-6′), 
133.9 (C-1′), 144.8 (C-1), 156.8 (C-4′), 158.1 (C-3), 161.1 (C-5); EM-IE (m/z) 258 [M+ (65)], 
121 (100). HREIMS [M]+(m/z) 258.1254 (calcd for C16H18O3 258.1256). 
 
4.1.3.3. 3-[2-(1,3-Benzodioxol-5-yl)ethyl]-5-methoxyphenol (3) 
 
Diphenylethane 3 was obtained as yellow crystals (0.74 g, yield 61.7%); mp 115 °C; UV 
(MeOH) λmax 281, 212 nm; IR (KBr) vmax 3306, 2927, 1592, 1484, 1243 cm−1; 1H NMR 
(400 MHz, CDCl3) δ 2.75–2.80 (4H, m, H-7, H-7′), 3.75 (3H, s, CH3O-5), 5.02 (1H, s, HO-3), 
5.92 (2H, s, –OCH2O–), 6.25 (2H, d, J = 2.2 Hz, H-2, H-6), 6.32 (1H, t, J = 2.2 Hz, H-4), 6.63 
(1H, dd, J = 7.9, 1.6 Hz, H-6′), 6.65 (1H, d, J = 1.6 Hz, H-5′), 6.72 (1H, d, J = 7.9 Hz, H-2′); 13C 
NMR (100 MHz, CDCl3) δ 37.2 (C-7′), 38.2 (C-7), 55.2 (CH3O-3), 99.0 (C-4), 100.7 (–OCH2O–
), 108.1 (C-6), 106.8 (C-2), 107.9 (C-2′), 108.9 (C-5′), 121.2 (C-6′), 135.5 (C-1′), 144.4 (C-1), 
145.7 (C-4′), 147.5 (C-3′), 156.5 (C-3), 160.9 (C-5); EM-IE (m/z) 272 [M+ (44)], 135 (100). 
HREIMS [M]+(m/z) 272.1045 (calcd for C16H16O4 272.1049). 
 
4.1.3.4. 4-[2-(3,5-Dimethoxyphenyl)ethyl]-1-ethoxy-2-methoxybenzene (4) 
 
Diphenylethane 4 was obtained as a yellow powder (1.0 g, yield 72.1%); mp 82 °C: UV 
(MeOH) λmax 279, 208 nm; IR (KBr) vmax 3072, 2935, 1598, 1469, 1136 cm−1; 1H NMR 
(400 MHz, CDCl3) δ 1.45 (3H, t, J = 6.8 Hz, CH3CH2O–), 2.84 (4H, br s, H-7, H-7′), 3.76 (6H, s, 
CH3O-3, CH3O-5), 3.83 (3H, s, CH3O-3′), 4.07 (2H, q, J = 6.8 Hz, CH3CH2O–), 6.31 (1H, 
t, J = 2.4 Hz, H-4), 6.34 (2H, d, J = 2.4 Hz, H-2, H-6), 6.67 (1H, d, J = 2.0 Hz, H-2′), 6.71 (1H, 
dd, J = 8.0, 2.0 Hz, H-6′), 6.79 (1H, d, J = 8.0 Hz, H-5′); 13C NMR (100 MHz, CDCl3) δ 14.8 
(CH3CH2O–), 37.3 (C-7), 38.4 (C-7′), 55.2 (CH3O-3, CH3O-5), 55.8 (CH3O-3′), 64.3 
(CH3CH2O–), 97.8 (C-4), 106.5 (C-2, C-6), 112.0 (C-2′), 112.7 (C-5′), 120.2 (C-6′), 134.3 (C-1′), 
144.2 (C-1), 146.4 (C-4′), 149.0 (C-3′), 160.7 (C-3, C-5); EM-IE (m/z) 316 [M+ (36)], 165 (100), 
137 (70). HREIMS [M]+(m/z) 316.1670 (calcd for C19H24O4 316.1675). 
 
4.1.3.5. 3-{2-[4-(Dimethylamino)phenyl]ethyl}-5-methoxyphenol (5) 
 
Compound 5 was obtained as a yellow powder (0.57 g, yield 48.2%); mp 146 °C; UV 
(MeOH) λmax 253, 208 nm; IR (KBr) vmax 3081, 2933, 1599, 1454, 1149 cm−1; 1H NMR 
(300 MHz, CDCl3) δ 2.77 (4H, br s, H-7, H-7′), 2.93 (6H, s, (CH3)2N–), 3.75 (3H, s, CH3O-5), 
5.70 (1H, br s, HO-3), 6.20 (1H, br s, H-4), 6.26 (1H, t, J = 2.4 Hz, H-2), 6.32 (1H, br s, H-6), 
6.82 (2H, d, J = 8.4 Hz, H-3′, H-5′), 7.09 (2H, d, J = 8.4 Hz, H-2′, H-6′); 13C NMR (75 MHz, 
CDCl3) δ 36.6 (C-7′), 38.1 (C-7), 41.6 ((CH3)2N–), 55.2 (CH3O-5), 98.9 (C-4), 106.6 (C-6), 
108.0 (C-2), 114.2 (C-3′, C-5′), 129.1 (C-2′, C-6′), 131.9 (C-1′), 144.6 (C-1), 148.3 (C-4′), 156.8 
(C-3), 160.8 (C-5); EM-IE (m/z) 271 [M+ (27)], 134 (100), 118 (6). HREIMS [M]+(m/z) 
271.1244 (calcd for C17H21NO2 271.1572). 
 
4.1.3.6. N-{4-[2-(3,5-Dimethoxyphenyl)ethyl]phenyl}-N,N-dimethylamine (6) 
 
Compound 6 was obtained as a white powder (0.77 g, yield 61.8%); mp 41 °C; UV 
(MeOH) λmax 254, 207 nm; IR (KBr) vmax 3430, 2927, 1596, 1522, 1346, 1159 cm−1; 1H NMR 
(400 MHz, CDCl3) δ 2.29 (4H, s, H-7, H-7′), 2.98 (6H, s, N(CH3)2), 3.76 (6H, s, CH3O-3, CH3O-
5), 6.28 (1H, m, H-4), 6.64 (2H, m, H-2, H-6), 6.73 (2H, d, J = 8.1 Hz, H-3′, H-5′), 7.12 (2H, 
d, J = 8.4 Hz, H-2′, H-6′); 13C NMR (100 MHz, CDCl3) δ 37.4 (C-7′), 38.0 (C-7), 41.3 
(N(CH3)2), 55.8 (CH3O-3, CH3O-5), 97.6 (C-4), 106.5 (C-2, C-6), 112.8 (C-3′, C-5′), 128.6 (C-
2′, C-6′), 131.6 (C-1′), 145.1 (C-1), 148.3 (C-4′), 161.5 (C-3, C-5); EM-IE (m/z) 285 [M+ (69)], 
134 (100), 118 (21). HREIMS [M]+(m/z) 285.1244 (calcd for C18H23NO2 285.1729). 
 
4.1.3.7. 3-[2-(1,3-Benzodioxol-5-yl)ethyl]phenol (7) 
 
This title compound was prepared following the same general procedure except that two 
equivalent of NaH (9.0 mmol) was used. Compound 7 was obtained as a yellow powder (0.58 g, 
yield 54.8%); mp 85 °C; UV (MeOH) λmax 281, 209 nm; IR (KBr) vmax 3367, 2858, 1483, 1244, 
1041 cm−1; 1H NMR (400 MHz, CDCl3) δ 2.82 (4H, s, H-7, H-7′), 4.63 (1H, s, HO-3), 5.92 (2H, 
s, –OCH2O–), 6.61 (5H, m, H-2, H-2′, H-3′, H-4, H-6′), 6.75 (1H, m, H-6), 7.14 (1H, m, H-
5); 13C NMR (100 MHz, CDCl3) δ 37.4 (C-7′), 38.0 (C-7), 100.7(–OCH2O–), 108.1 (C-5′), 108.9 
(C-2′), 112.8 (C-4), 115.3 (C-2), 120.9 (C-6), 121.2 (C-6′), 129.5 (C-5), 135.5 (C-1′), 143.5 (C-
1), 145.6 (C-4′), 147.5 (C-3′), 155.5 (C-3); EM-IE (m/z) 242 [M+ (64)], 135 (100), 105 (8), 77 
(22). HREIMS [M]+(m/z) 242.0941 (calcd for C15H14O3 242.09243). 
 
4.1.3.8. 1,3-Dimethoxy-5-[2-(4-methoxyphenyl)ethyl]benzene (8) 
 
Compound 8 was obtained as an amber oil (0.53 g, yield 44.5%); UV (MeOH) λmax 277, 208 nm; 
IR (KBr) vmax 2998, 2935, 1596, 1463, 1246, 1153 cm−1; 1H NMR (300 MHz, CDCl3) δ 2.80–
2.87 (4H, m, H-7, H-7′), 3.76 (6H, s, CH3O-3, CH3O-5), 3.78 (3H, s, CH3O-4′), 6.30–6.34 (3H, 
m, H-2, H-4, H-6), 6.82 (2H, d, J = 8.7 Hz, H-3′, H-5′), 7.10 (2H, d, J = 8.7 Hz, H-2′, H-6′); 13C 
NMR (75 MHz, CDCl3) δ 36.7 (C-7), 38.4 (C-7′), 55.21 (CH3O-3, CH3O-5), 55.23 (CH3O-4′), 
97.9 (C-4), 106.5 (C-2, C-6), 113.7 (C-3′, C-5′), 129.3 (C-2′, C-6′), 133.8 (C-1), 144.2 (C-1′), 
157.8 (C-4′), 160.7 (C-3, C-5); EM-IE (m/z) 272 [M+ (24)], 151 (6), 121 (100), 91 (14), 77 (20). 
HREIMS [M]+(m/z) 272.1410 (calcd for C17H20O3 272.1412). 
 
4.1.3.9. 3-[2-(4-Ethoxy-3-methoxyphenyl)ethyl]phenol (9) 
 
This title compound was prepared following the same general procedure except that two 
equivalent of NaH (9.0 mmol) was used. Compound 9 was obtained as yellow crystals (0.67 g, 
yield 56.3%); mp 54 °C; UV (MeOH) λmax 279, 207 nm; IR (KBr) vmax 3536, 2944, 1590, 1516, 
1362, 1229 cm−1; 1H NMR (400 MHz, CDCl3) δ 1.45 (3H, t, J = 7.0 Hz, CH3CH2O–), 2.84 (4H, 
s, H-7, H-7′), 3.84 (3H, s, CH3O-3), 4.07 (2H, q, J = 7.0 Hz, CH3CH2O–), 4.82 (1H, br s, HO-3), 
6.64–6.66 (2H, m, H-2′, H-4), 6.66–6.72 (2H, m, H-2, H-6), 6.75 (1H, d, J = 7.5 Hz, H-6′), 6.79 
(1H, d, J = 7.5 Hz, H-5′), 7.14 (1H, td, J = 7.5, 1.2 Hz, H-5); 13C NMR (100 MHz, CDCl3) δ 14.8 
(CH3CH2O–), 37.3 (C-7), 37.9 (C-7′), 55.8 (CH3O–), 64.3 (CH3CH2O–), 112.0 (C-2′), 112.8 (C-
4), 115.4 (C-2, C-5′), 120.2 (C-6), 120.9 (C-6′), 129.4 (C-5), 134.3 (C-1′), 143.7 (C-1), 146.4 (C-
4′), 148.9 (C-3′), 155.5 (C-3); EM-IE (m/z) 272 [M+ (37)], 165 (96), 137 (100), 107 (15), 77 (10). 
HREIMS [M]+(m/z) 272.1414 (calcd for C17H20O3 272.1412). 
 
4.1.3.10. 3-[2-(4-Ethoxy-3-methoxyphenyl)ethyl]-5-methoxyphenol (10) 
 
Compound 10 was obtained as an amber oil (0.81 g, yield 60.8%): UV (MeOH) λmax 280, 
208 nm; IR (KBr) vmax 3451, 2935, 1600, 1456, 1145 cm−1; 1H NMR (400 MHz, CDCl3) δ 1.45 
(3H, t, J = 7.1 Hz, CH3CH2O–), 2.82 (4H, br s, H-7, H-7′), 3.75 (3H, s, CH3O-3′), 3.85 (3H, s, 
CH3O-3), 4.07 (2H, q, J = 7.1 Hz, CH3CH2O–), 4.82 (1H, s, HO-3), 6.25 (2H, d, J = 1.8 Hz, H-2, 
H-6), 6.32 (1H, t, J = 1.8 Hz, H-4), 6.66 (1H, d, J = 2.0 Hz, H-2′), 6.69 (1H, dd, J = 8.1, 2.0 Hz, 
H-6′), 6.79 (1H, d, J = 8.1 Hz, H-5′); 13C NMR (100 MHz, CDCl3) δ 15.1 (CH3CH2O–), 37.4 (C-
7′), 38.4 (C-7), 55.5 (CH3O-3), 56.2 (CH3O-3′), 64.7 (CH3CH2O–), 99.3 (C-4), 107.1 (C-6), 
108.2 (C-2), 112.6 (C-2′), 113.3 (C-5′), 120.6 (C-6′), 134.6 (C-1′), 144.8 (C-1), 146.8 (C-4′), 
149.4 (C-3′), 156.8 (C-3), 161.2 (C-5); EM-IE (m/z) 302 [M+ (38)], 165 (90), 137 (100), 122 
(19), 94 (32), 77 (30). HREIMS [M]+(m/z) 302.1512 (calcd for C18H22O4 302.1518). 
 
4.1.4. Synthesis of diphenylmethanes 13 and 14 
 
4.1.4.1. Synthesis of intermediate 1,3-dimethoxy-5-[(2-methoxyphenoxy)methyl]benzene (26) 
 
To a solution of 8.5 g (36.8 mmol) of 3,5-dimethoxybenzyl bromide (25) in acetone (65 mL), 
5.0 g (40.3 mmol) of guaiacol, 5.5 g (39.9 mmol) of K2CO3, and 1.0 g (6.1 mmol) of KI were 
added. The mixture was stirred and heated to reflux for 10 h; afterward, the solvent was 
removed in vacuo. To the previous resulting mixture 30 mL of water were added at room 
temperature and extracted with EtOAc (2 × 25 mL). The combined organic layers were 
consecutively washed with an aqueous solution of NaOH (5%, 20 mL), and brine (2 × 25 mL), 
and finally dried over anh. Na2SO4. After elimination of the solvent in vacuo, the crude reaction 
mixture was purified by flash column chromatography on silica gel (hexane-EtOAc, 9:1; for 
1.0 g of crude reaction, 30 g of silica gel were packed in the column) to give compound 26 
(6.72 g, yield 66.7%). UV (MeOH) λmax 275, 207 nm; IR (KBr) vmax 2939, 2837, 1598, 1505, 
1456, 1251 cm−1; 1H NMR (400 MHz, CDCl3) δ 3.78 (6H, s, CH3O-3, CH3O-5), 3.89 (3H, s, 
CH3O-2′), 5.10 (2H, s, –CH2O–), 6.38 (1H, t, J = 2.4 Hz, H-4), 6.60 (2H, d, J = 2.4 Hz, H-2, H-
6), 6.81–6.95 (4H, m, ArH); 13C NMR (100 MHz, CDCl3) δ 55.3 (CH3O-3, CH3O-5), 55.9 
(CH3O-2′), 71.0 (–CH2O–), 99.8 (C-4), 104.9 (C-2, C-6), 111.9 (C-3′), 114.3 (C-6′), 120.8 (C-
4′), 121.5 (C-5′), 139.8 (C-1), 148.1 (C-2′), 149.7 (C-1′), 160.9 (C-3, C-5); EM-IE (m/z) 274 
[M+ (27)], 151 (100), 77 (43).HREIMS [M]+(m/z) 274.1204 (calcd for C16H18O4 274.1205). 
 
4.1.4.2. 2-(3,5-Dimethoxybenzyl)-6-methoxyphenol (13) and 4-(3,5-dimethoxybenzyl)-2-
methoxyphenol (14) 
 
1.5 g (5.5 mmol) of 26, 1.7 mL (29.1 mmol) of H3PO4, and 18 mL of toluene were mixed at 
room temperature. The mixture was stirred and heated under reflux for 6.5 h. The resulting 
solution was allowed to cool to room temperature; then, 15 mL of water and Na2CO3, to pH 12, 
were added to the reaction mixture, from which the crude products were extracted with EtOAc 
(2 × 15 mL). The combined organic layers were washed with brine (10 mL), and dried (Na2SO4). 
After solvent removal, the residue was purified by flash chromatography (hexane-EtOAc, 9:1; 
for 1.0 g of crude reaction, 30 g of silica gel were packed in the column) to give products 
diphenylmethane 13 (0.4 g, yield 26.8%) as yellow powder mp 80 °C, and 14 as a colorless oil 
(36 mg, yield 2.4%). 13: UV (MeOH) λmax 273, 226 nm; IR (KBr) vmax 3406, 2957, 1590, 1468, 
1208, 1159 cm−1; 1H NMR (400 MHz, CDCl3) δ 3.74 (3H, s, CH3O-3′), 3.75 (6H, s, CH3O-3, 
CH3O-5), 3.95 (2H, s, –CH2–), 5.52 (1H, br s, HO-2′), 6.31 (1H, t, J = 2.3 Hz, H-4), 6.35 (2H, 
d, J = 2.3 Hz, H-2, H-6), 6.66 (1H, dd, J = 8.0, 1.7 Hz, H-6′), 6.84 (1H, dd, J = 8.0, 1.7 Hz, H-
4′), 6.94 (1H, t, J = 8.0 Hz, H-5′); 13C NMR (100 MHz, CDCl3) δ 35.7 (–CH2–), 55.2 (CH3O-3, 
CH3O-5), 61.3 (CH3O-3′), 97.9 (C-4), 107.0 (C-2, C-6), 113.9 (C-4′), 122.4 (C-5′), 124.9 (C-6′), 
133.5 (C-1′), 142.9 (C-1), 145.4 (C-2′), 148.9 (C-3′), 160.8 (C-3, C-5); EM-IE (m/z) 274 
[M+ (100)], 151 (72.5), 115 (41). HREIMS [M]+(m/z) 274.1206 (calcd for C16H18O4 274.1205). 
14: UV (MeOH) λmax 280, 219 nm; IR (KBr), vmax 3437, 2935, 1594, 1511, 1460, 1152 cm−1; 1H 
NMR (400 MHz, CDCl3): δ 3.75 (6H, s, CH3O-3, CH3O-5), 3.88 (3H, s, CH3O-3′), 3.94 (2H, s, –
CH2–), 5.72 (1H, s, HO-4′), 6.30 (1H, t, J = 2.4 Hz, H-4), 6.43 (2H, d, J = 2.4 Hz, H-2, H-6), 
6.72, (1H, dd, J = 6.8, 2.4 Hz, H-6′), 6.74–6.80 (2H, m, H-2′, H-5′); 13C NMR (100 MHz, 
CDCl3): δ 35.6 (–CH2–), 55.2 (CH3O-3, CH3O-5), 56.0 (CH3O-3′), 97.8 (C-4), 107.0 (C-2, C-6), 
108.7 (C-2′), 119.4 (C-5′), 122.7 (C-6′) 126.6 (C-1′), 143.2 (C-1), 143.4 (C-4′), 146.4 (C-3′), 
160.6 (C-3, C-5); EM-IE (m/z) 274 [M+ (29)], 151 (100), 115 (20.5). HREIMS [M]+(m/z) 
274.1200 (calcd for C16H18O4 274.1205). 
 
4.1.5. General procedure for the synthesis of 1,3-diphenylpropenones 16–19 
 
Equimolar portions of acetophenones 27a–27c (10 mmol) and aromatic aldehydes 24b, 24c or 
24g (10 mmol) were dissolved in ethanol (15 mL). 5 mL of a 40% aqueous KOH solution was 
then slowly added drop wise. The mixture was stirred and heated to reflux for 10 h. The mixture 
of reaction was poured into ice-water and acidified with cold diluted HCl (2N). The precipitate 
was filtered and purified by flash column chromatography on silica gel (hexane-EtOAc, 9:1) to 
give the final products 16–19. For 1.0 g of crude reaction, 30 g of silica gel were packed in the 
column. 
 
4.1.5.1. (2E)-1-(4-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (16) 
 
Compound 16 (1.96 g, yield 77.4%) was obtained as yellow powder; mp 190 °C; UV 
(MeOH) λmax 344, 236 nm; IR (KBr) vmax 3123, 2839, 1645, 1563, 1429, 1166 cm−1; 1H NMR 
(400 MHz, CDCl3) δ 3.89 (3H, s, CH3O-4), 4.89 (1H, s, HO-4′), 6.96–6.98 (4H, m, H-3, H-3′, H-
5, H-5′), 7.45 (1H, d, J = 15.6 Hz, CH-α), 7.63 (2H, d, J = 8.7 Hz, H-2, H-6), 7.81 (1H, 
d, J = 15.9 Hz, CH-β), 8.03 (2H, d, J = 8.7 Hz, H-2′, H-6′); 13C NMR (100 MHz, 
CDCl3) δ 55.4 (CH3O-4), 114.4 (C-3, C-5), 115.4 (C-3′, C-5′), 119.5 (C-α), 127.7 (C-1), 130.1 
(C-1′), 130.7 (C-2, C-6), 131.0 (C-2′, C-6′), 144.1 (C-β), 159.7 (C-4), 161.6 (C-4′), 188.9 (C
O); EM-IE (m/z) 254 [M+ (100)], 239 (21), 161 (18), 121 (20). HREIMS [M]+(m/z) 254.0950 
(calcd for C16H14O3 254.0943). 
 
4.1.5.2. (2E)-3-(3-hydroxy-4-methoxyphenyl)-1-(3-hydroxy-5-methoxyphenyl)prop-2-en-1-one 
(17) 
 
Chalcone17 (2.16 g, yield 72.0%) was obtained as yellow powder; mp 161 °C; UV 
(MeOH) λmax 356, 207 nm; IR (KBr) vmax 3476, 3263, 2840, 1646, 1562, 1266 cm−1; 1H NMR 
(400 MHz, CD3OD) δ 3.82 (3H, s, CH3O-4), 3.91 (3H, s, CH3O-5′), 6.60 (1H, t, J = 2.1 Hz, H-
4′), 6.98 (1H, d, J = 8.3 Hz, H-5), 7.01–7.03 (2H, m, H-2′, H-6′), 7.19 (1H, dd, J = 8.3, 2.1 Hz, 
H-6), 7.21 (1H, d, J = 2.1 Hz, H-2), 7.41 (1H, d, J = 15.7 Hz, CH-α), 7.67 (1H, 
d, J = 15.7 Hz, CH-β); 13C NMR (100 MHz, CD3OD) δ 54.5 (CH3O-5′), 54.9 (CH3O-4), 104.6 
(C-6′), 105.5 (C-4′), 107.6 (C-2′), 111.1 (C-5), 113.7 (C-2), 119.4 (C-α), 122.14 (C-6), 127.9 (C-
1), 140.7 (C-1′), 145.4 (C-β), 146.6 (C-3), 150.5 (C-4), 158.7 (C-3′), 161.2 (C-5′), 191.0 (C O); 
EM-IE (m/z) 300 [M+ (100)], 285 (34), 177 (35), 142 (41). HREIMS [M]+(m/z) 300.0980 (calcd 
for C17H16O5 300.0998). 
 
4.1.5.3. (2E)-1-(3-hydroxy-5-methoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one 
(18) 
 
Chalcone 18 (1.91 g, yield 63.7%) was obtained as yellow powder; mp 161–162 °C; UV 
(MeOH) λmax 360, 207 nm; IR (KBr) vmax 3407, 2943, 1648, 1565, 1428, 1149 cm−1; 1H NMR 
(400 MHz, CD3OD) δ 3.83 (3H, s, CH3O-3), 3.93 (3H, s, CH3O-5′), 6.60 (1H, t, J = 2.0 Hz, H-
4′), 6.84 (1H, d, J = 8.4 Hz, H-6), 7.04 (1H, t, J = 2.0 Hz, H-2′), 7.06 (1H, t, J = 2.0 Hz, H-6′), 
7.22 (1H, dd, J = 8.4, 2.0 Hz, H-5), 7.33 (1H, d, J = 2.0 Hz, H-2), 7.46 (1H, d, J = 15.6 Hz, 
CH-α), 7.71 (1H, d, J = 15.6 Hz, CH-β); 13C NMR (100 MHz, CD3OD) δ 54.5 (CH3O-5′), 
55.1 (CH3O-3), 104.7 (C-2′), 105.4 (C-4′), 107.6 (C-6′), 110.8 (C-2), 115.2 (C-5), 118.8 (C-α), 
123.5 (C-6), 126.8 (C-1), 140.3 (C-1′), 145.9 (C-β), 148.0 (C-4), 149.7 (C-3), 158.6 (C-3′), 161.1 
(C-5′), 191.2 (C O); EM-IE (m/z) 300 [M+ (100)], 177 (28), 145 (23). HREIMS [M]+(m/z) 
300.0980 (calcd for C17H16O5 300.0998). 
 
4.1.5.4. (2E)-3-(1,3-benzodioxol-5-yl)-1-(3-hydroxyphenyl)prop-2-en-1-one (19) 
 
To a solution of (1.36 g, 10 mmol) 4′-hydroxyacetophenone (27c), (1.5 g, 10 mmol) of 3,4-
(methylenedioxy)benzaldehyde (24c) in ethanol (15 mL), an aqueous solution of KOH (40%, 
5 mL) was added slowly. The mixture was stirred and heated to reflux for 10 h, and then the 
suspension was poured into ice-water. The precipitate was filtered and dried to yield (E)-3′-
hydroxy-3,4-methylenedioxydiphenylpropenone (19) (1.7 g, 63.7%) as an amorphous yellow 
powder; UV (MeOH) λmax 361, 206 nm; IR (KBr) vmax 3406, 2945, 1644, 1563 cm−1; 1H NMR 
(400 MHz, CDCl3) δ 5.18 (1H, br s, HO-3′), 6.07 (2H, s, –OCH2O–), 6.89 (1H, d, J = 7.9 Hz, H-
5), 6.92 (1H, dd, J = 7.3, 3.8 Hz, H-4′), 7.09 (1H, dd, J = 8.2, 1.6 Hz, H-6′), 7.18 (1H, 
dd, J = 7.9, 1.8 Hz, H-6), 7.27 (1H, d, J = 2.0 Hz, H-2), 7.37 (1H, dd, J = 5.6, 4.9 Hz, H-2′), 7.45 
(1H, d, J = 15.6 Hz, CH-α),7.59 (1H, t, J = 7.8 Hz, H-5′),7.88 (1H, d, J = 15.8 Hz, CH-β). 
HREIMS [M]+(m/z) 268.2639 (calcd for C16H12O4 268.2640). 
 
4.1.6. Synthesis of 1,3-diphenylpropanes 20–22 
 
4.1.6.1. 4-[3-(4-Methoxyphenyl)propyl]phenol (20) 
 
Chalcone 16 (3.0 g) was dissolved in a solution of H2SO4 (2.0 mL) in EtOH (100 mL) and 
hydrogenated at 60 lb/in2 (60 °C) over 10% palladium on carbon (0.3 g) for 4 h; the catalyst was 
filtered and the solvent removed in vacuo. The resulting solution was then tried with 50 mL of 
water and the crude products were extracted with EtOAc (2 × 25 mL). The combined organic 
layers were washed with brine (20 mL), and dried (Na2SO4). After solvent removal, the residue 
was purified by flash chromatography to give diphenylpropane 20: (2.67 g, yield 92.4%) as 
yellow powder; mp 48 °C; UV (MeOH) λmax 277, 226 nm; IR (KBr) vmax 3418, 2941, 1608, 
1512, 1353, 1216 cm−1; 1H NMR (400 MHz, CDCl3) δ 1.80–1.90 (2H, m, H-8), 2.50–2.60 (4H, 
m, H-7, H-7′), 3.78 (3H, s, CH3O-4′), 4.41 (1H, br s, HO-4), 6.73 (2H, d, J = 8.8 Hz, H-3, H-5), 
6.82 (2H, d, J = 8.8 Hz, H-3′, H-5′), 7.02 (2H, d, J = 8.8 Hz, H-2, H-6), 7.08 (2H, d, J = 8.8 Hz, 
H-2′, H-6′); 13C NMR (100 MHz, CDCl3) δ 33.4 (C-8), 34.8 (C-7, C-7′), 55.3 (CH3O-4′), 113.7 
(C-3′, C-5′), 115.1 (C-3, C-5), 129.3 (C-2′, C-6′), 129.4 (C-2, C-6), 134.4 (C-1′), 134.5 (C-1), 
153.5 (C-4), 157.5 (C-4′); EM-IE (m/z) 242 [M+ (71)], 135 (18), 121 (100), 107 (24). HREIMS 
[M]+(m/z) 242.1301 (calcd for C16H18O2 242.1307). 
 
4.1.6.2. 4-[3-(1,3-Benzodioxol-5-yl)propyl]phenol (21) 
 
Compound 19 (1.5 g, 5.6 mmol) was dissolved in a solution of H2SO4 (1.0 mL) in EtOH 
(50 mL), and hydrogenated at 60 lb/in2 (60 °C) over 10% palladium on carbon (0.15 g) for 4 h. 
The catalyst was filtered off and the filtrate evaporated. The resulting solution was then tried 
with 25 mL of water and the crude products were extracted with EtOAc (2 × 25 mL). The 
combined organic layers were washed with brine (20 mL), and dried (Na2SO4). After solvent 
removal, the residue was purified by flash chromatography to give diphenylpropane 21 (1.48 g, 
yield 58%) as yellow powder; mp 84 °C: UV (MeOH) λmax 281, 209 nm; IR (KBr) vmax 3477, 
3368, 2928, 1586, 1500, 1483, 1244 cm−1; 1H NMR (400 MHz, CDCl3) δ 1.26 (2H, m, H-8), 
2.82 (4H, s, H-7, H-7′), 4.63 (1H, br s, HO-3), 5.92 (2H, s, –OCH2O–), 6.61 (1H, dd, J = 8.0, 
1.6 Hz, H-6′), 6.64–6.68 (3H, m, H-2, H-2′, H-4), 6.72 (1H, d, J = 8.0 Hz, H-5′), 6.75 (1H, 
d, J = 7.6 Hz, H-6), 7.14 (1H, dt, J = 7.6, 2.4 Hz, H-5); 13C NMR (100 MHz, CDCl3) δ 37.4 (C-
8), 37.9 (C-7, C-7′), 100.7 (–OCH2O–), 108.1 (C-5′), 112.5 (C-2′), 112.8 (C-4), 115.3 (C-2), 
120.9 (C-6), 121.1 (C-6′), 129.5 (C-5), 135.5 (C-1′), 143.6 (C-1), 145.6 (C-4′), 147.5 (C-3′), 
155.4 (C-3); EM-IE (m/z) 256 [M+ (60)], 149 (100), 119 (16). HREIMS [M]+(m/z) 256.1090 
(calcd for C16H16O3 256.1099). 
 
4.1.6.3. 4-[3-(3-Hydroxy-5-methoxyphenyl)propyl]-2-methoxyphenol (22) 
 
Compound 22 (crystalline solid, mp 77 °C, 0.25 g, yield 54.2%) was prepared from 
chalcone 18 (0.48 g) following the method described for 21. UV (MeOH) λmax 279, 207 nm; IR 
(KBr) vmax 3355, 3039, 2931, 1611, 1591, 1513, 1455, 1196, 813 cm−1; 1H NMR (400 MHz, 
CDCl3) δ 1.89 (2H, q, J = 7.6 Hz, H-8), 2.55 (2H, t, J = 7.6 Hz, H-7), 2.56 (2H, t, J = 7.6 Hz, H-
7′), 3.76 (3H, s, CH3O-3′), 3.86 (3H, s, CH3O-5), 5.49 (2H, br s, HO-3, HO-4′), 6.24 (2H, m, H-
2, H-4), 6.32 (1H, d, J = 3.0 Hz, H-2′), 6.67 (2H, m, H-6, H-6′), 6.83 (1H, d, J = 8.0 Hz, H-
5′). 13C NMR (100 MHz, CDCl3) δ 32.8 (C-8), 35.0 (C-7, C-7′), 35.4 (C-7, C-7′), 55.2 (CH3O-
3′), 55.9 (CH3O-5), 98.2 (C-4), 106.8 (C-6), 107.9 (C-2), 111.0 (C-2′), 114.2 (C-5′), 120.9 (C-6′), 
134.2 (C-1′), 143.6 (C-1), 145.1 (C-4′), 146.3 (C-3′), 156.6 (C-3), 160.8 (C-5); EM-IE (m/z) 288 
[M+ (9)], 150 (4), 138 (100), 122 (4), 77 (7), 65 (4). HREIMS [M]+(m/z) 288.3378 (calcd for 
C17H20O4 288.3380). 
 
4.2. Biological study 
 
4.2.1. Phosphodiesterase activity assay 
 
Phosphodiesterase activity was measured according to the method described by Rivero and 
coworkers with some modifications [12]. Briefly, CaM (0.08 μg) was incubated with 0.015 units 
of PDE1 from bovine brain during 30 min in 40 μL of assay solution containing 0.063 units 
of 5′-nucleotidase (Crotalus atrox venom from Sigma), 45 mM Tris–HCl, 5.6 mM magnesium 
acetate, 45 mM imidazole, 2.5 mM calcium chloride and 10 mM BSA, pH 7.0. Tested 
compounds were then added to the assay medium at 0.5, 1, 2, 3, 4, 7, 13, 20, 32, 50, and 65 mM 
in MeCN-water (1:1), and the samples incubated during 30 min; thereafter 10 μL of 
10.8 mM cAMP were added to start the assay. After 15 min, the assay was stopped by the 
addition of 190 μL of malachite green solution. The amount of inorganic phosphate released was 
measured at 700 nm, correlated with the activity of the PDE1. All the results are expressed as the 
mean of at least six experiments ± SEM. The IC50 (concentration inhibiting by 50% the activity 
of the enzyme) values were determined by non-linear regression analysis by fitting to 
hyperbolic inhibition. 
 
4.2.2. Steady-state fluorescence (biosensor CaM) 
 
All measurements were conducted with an ISS-PC1 spectrofluorometer (ISS, Champaign, IL), 
with sample stirring at 37 °C. The protein hCaM M124C–mBBr (5 μM) [14] was incubated in a 
phosphate buffer (100 mM; pH 5.1) and 10 mM CaCl2. Fluorescence emission spectra were 
acquired with excitation and emission slit widths of 4 and 8 nm, respectively. The excitation 
wavelength was 381 nm and emission wavelengths were measured from 400 to 550 nm. The 
fractional degree of saturated hCaM M124C–mBBr with ligand (y), was calculated by changes in 
fluorescence upon ligand binding according to y = (F − F0)/(F∞ − F0), where F∞ represents 
the fluorescence intensity at saturation of the ligand, y was plotted as a function of the inhibitor 
concentration, and the apparent constants (Km) concentration that produces an effect that is 50% 
of maximum effect (Emax) were obtained by fitting to equation [20].  
 
𝑦𝑦 = 𝐸𝐸𝑚𝑚𝑚𝑚𝑚𝑚𝐿𝐿
ℎ
𝐾𝐾𝑚𝑚ℎ +𝐿𝐿ℎ
  
 
where y represents the fractional degree of fluorescence intensity at 470 nm, Km is the apparent 
constant for the ligands, Emax is the maximal value of effect, L is the concentrations of the ligand 
and h is the Hill coefficient. The data were analyzed using the program Origin 8.0 (OriginLab, 
Northampton, MA). 
 
4.3. Docking 
 
To generate more accurate and physically realistic models of the protein CaM (PDB code 1LIN), 
after several iterations of rebuilding and refinement, we perform a final all-atom refinement of 
CaM with the idealization application of the Rosetta3.1 release [21]. This application rebuilds 
molecules using ideal bond lengths, bond angles, and torsion angles. The starting conformation 
of the ligands was optimized using the program Gaussian 09, revision A.02 (Gaussian Inc., 
Wallingford, CT) at DTF B3LYP/3-21g level of theory. Blind docking was carried out using 
AutoDock4 version 4.2 software (http://autodock.scripps.edu/) [15], [16] using the default 
parameters the Lamarkian genetic algorithm with local search, number of individuals in 
population (150), maximum number of energy evaluations (2.5 million), maximum number of 
generations (27 000), rate of gene mutation (0.02), rate of crossover (0.8) and 100 runs for 
docking. The initial grid box size was 60 Ǻ × 60 Ǻ × 60 Ǻ in the x, y and z dimensions. The 
refined docking analysis was performed in a smaller grid box, with 30 Ǻ × 30 Ǻ × 30 Ǻ 
dimensions, centered in the ligand. All calculations were made using a parallel distributed 
memory supercomputer (Kanbalam, Dirección General de Cómputo y de Tecnologías de 
Información y Comunicación, UNAM) which contains 1368 processors AMD Opteron, around 3 
terabyte of memory and 160 terabyte of storage (http://www.super.unam.mx/). 
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